Read by QxMD icon Read


Yanhong Li, Di Zhang, Ling Xu, Lin Dong, Ji Zheng, Yikong Lin, Jiefang Huang, Yanyun Zhang, Yu Tao, Xingxing Zang, Dajin Li, Meirong Du
Mesenchymal stem cells (MSCs), which are pluripotent cells with immunomodulatory properties, have been considered good candidates for the therapy of several immune disorders, such as inflammatory bowel diseases, concanavalin A-induced liver injury, and graft-versus-host disease. The embryo is a natural allograft to the maternal immune system. A successful pregnancy depends on the timely extinction of the inflammatory response induced by embryo implantation, followed by the switch to a tolerant immune microenvironment in both the uterus and the system...
February 18, 2019: Cellular & Molecular Immunology
Hao Chi Zhang, Wenyi Luo, Yinghong Wang
BACKGROUND: Immune checkpoint inhibitors (ICPIs), used to treat different advanced malignancies, are associated with a wide range of immune-related adverse reactions (irAEs) that deserve close monitoring of patients. Gastrointestinal reactions and hepatotoxicity may occur, which warrant careful evaluation to confirm the etiology and attribution to ICPIs as these events could affect future management. CASE PRESENTATION: We describe a case of a patient with prostate adenocarcinoma, treated with dual ICPIs comprised of ipilimumab and nivolumab, who developed elevated liver enzymes in the context of infliximab therapy prescribed to treat gastrointestinal irAE from his ICPIs...
February 18, 2019: Journal for Immunotherapy of Cancer
Tomer Adar, David Faleck, Saranya Sasidharan, Kelly Cushing, Nienke Z Borren, Niharika Nalagatla, Ryan Ungaro, Wayne Sy, Samuel C Owen, Anish Patel, Benjamin L Cohen, Ashwin N Ananthakrishnan
BACKGROUND: The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population. AIM: To compare safety and efficacy of tumor necrosis factor α antagonist (anti-TNF) or vedolizumab (VDZ) in patients with IBD >60 years of age. METHODS: This retrospective study included patients with Crohn's disease (CD) or ulcerative colitis (UC) initiating anti-TNF or VDZ therapy ≥60 years of age at three study sites...
February 17, 2019: Alimentary Pharmacology & Therapeutics
Chang Sik Yu, Sung Woo Jung, Jong Lyul Lee, Seok-Byung Lim, In Ja Park, Yong Sik Yoon, Chan Wook Kim, Suk Kyun Ynag, Byung Duk Ye, Sang Hyung Park, Minkyu Han, Jin Cheon Kim
Background: Many patients with Crohn's disease (CD) are treated with medications, including steroids, immunomodulators, and anti-tumor necrosis factor alpha (anti-TNF-α) agents, at the time of surgery. This study evaluated the effects of these medications on postoperative complications in CD patients. Methods: This retrospective study analyzed patients who underwent bowel resection for CD between January 2006 and December 2015. Postoperative complications were defined as a Clavien-Dindo classification of grade 2A or higher within the first 30 days after surgery...
February 8, 2019: Inflammatory Bowel Diseases
Caroline Otto, András Tárnok, Adrienn Erős, Zsolt Szakács, Áron Vincze, Nelli Farkas, Patricia Sarlós
PURPOSE: To evaluate the effect of our current transition process on clinical outcomes in adolescent patients with inflammatory bowel diseases (IBD). DESIGN AND METHODS: Two groups of patients with IBD diagnosed in pediatric care were compared retrospectively: Group A patients did not attend the transition process, while Group B patients entered the planned transition service. Outcomes at 1-year after transfer to adult care were evaluated. RESULTS: Forty-five patients with IBD diagnosed under the age of 18 years were identified of whom 35 had Crohn's disease and 10 had ulcerative colitis...
February 9, 2019: Journal of Pediatric Nursing
Uday N Shivaji, Caroline L Sharratt, Tom Thomas, Samuel C L Smith, Marietta Iacucci, Gordon W Moran, Subrata Ghosh, Neeraj Bhala
BACKGROUND: Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab and golimumab are currently licensed anti-TNF therapies. Biosimilar anti-TNF monoclonal antibodies are increasingly used. Anti-TNF therapies are widely used and their adverse effects are well characterised, and may cause significant morbidity and mortality in a small proportion of exposed patients. Gastroenterologists need to understand the mechanisms for these effects, recognise these swiftly and manage such events appropriately...
February 8, 2019: Alimentary Pharmacology & Therapeutics
Roni Weisshof, Maya Aharoni Golan, Philip H Sossenheimer, Katia El Jurdi, Jacob E Ollech, Joel Pekow, Russel D Cohen, Atsushi Sakuraba, Sushila Dalal, David T Rubin
BACKGROUND AND AIMS: Many inflammatory bowel disease (IBD) patients do not respond to medical therapy. Tofacitinib is a first-in-class, partially selective inhibitor of Janus kinase, recently approved for treating patients with ulcerative colitis (UC). We describe our experience with the use of tofacitinib for treatment of patients with moderate-to-severe IBD. METHODS: This is a retrospective, observational study of the use of tofacitinib in IBD. Patients with medically resistant IBD were treated orally with 5 mg or 10 mg twice daily...
February 7, 2019: Digestive Diseases and Sciences
C Chavarría, M J Casanova, M Chaparro, M Barreiro-de Acosta, E Ezquiaga, L Bujanda, M Rivero, F Argüelles-Arias, M D Martín-Arranz, M P Martínez-Montiel, M Valls, R Ferreiro-Iglesias, J Llaó, I Moraleja-Yudego, F Casellas, B Antolín-Melero, X Cortés, R Plaza, J R Pineda, M Navarro-Llavat, S García-López, P Robledo-Andrés, I Marín-Jiménez, V García-Sánchez, O Merino, A Algaba, M R Arribas-López, J M Banales, B Castro, L Castro-Laria, R Honrubia, P Almela, J P Gisbert
AIMS: To determine the prevalence of fatigue in patients with inflammatory bowel disease (IBD), to identify the factors associated with fatigue and its severity, to assess the impact of fatigue on quality of life (QoL) and to evaluate the relationship between fatigue and sleep disorders. METHODS: Prospective multicenter study conducted at 22 Spanish centers. Consecutive patients followed at IBD Units were included. Fatigue was evaluated with the Fatigue Severity Scale (FSS), and the Fatigue Impact Scale (FIS)...
February 5, 2019: Journal of Crohn's & Colitis
Jessica Breton, Arthur Kastl, Natalie Hoffmann, Rachel Rogers, Andrew B Grossman, Petar Mamula, Judith R Kelsen, Robert N Baldassano, Lindsey Albenberg
Background: Recent studies have shown that oral combination antibiotics may improve disease course in refractory inflammatory bowel disease (IBD). Here, we describe the use of combination oral antibiotics as salvage therapy in refractory ulcerative colitis (UC), Crohn's colitis, and IBD-unclassified (IBD-U) at a large pediatric IBD center. Methods: Clinical response, disease activity indices, adverse events, and clinical outcomes were measured up to 1 year after antibiotic treatment in this retrospective cohort study of children with medically refractory IBD colitis...
February 4, 2019: Inflammatory Bowel Diseases
Luca Zanoli, Kadir Ozturk, Maria Cappello, Gaetano Inserra, Giulio Geraci, Antonio Tuttolomondo, Daniele Torres, Antonio Pinto, Andrea Duminuco, Gaia Riguccio, Musa B Aykan, Giuseppe Mulé, Santina Cottone, Alessandra F Perna, Stephane Laurent, Pasquale Fatuzzo, Pietro Castellino, Pierre Boutouyrie
Background Inflammatory bowel disease ( IBD ) is characterized by a low prevalence of traditional risk factors, an increased aortic pulse-wave velocity ( aPWV ), and an excess of cardiovascular events. We have previously hypothesized that the cardiovascular risk excess reported in these patients could be explained by chronic inflammation. Here, we tested the hypothesis that chronic inflammation is responsible for the increased aPWV previously reported in IBD patients and that anti-TNFa (anti-tumor necrosis factor-alpha) therapy reduce aPWV in these patients...
February 5, 2019: Journal of the American Heart Association
Jaemin Lee, Han-Seok Choi, Jinkyung Lee, Jimin Park, Sang-Back Kim, Myoung-Sook Shin, Sullim Lee, Gwi Seo Hwang, Bon Am Koo, Ki Sung Kang
Many medicinal plants have been used traditionally in East Asia for the treatment of gastrointestinal disease and inflammation. The aim of this study was to evaluate the anti-inflammatory activity of 350 extracts (175 water extracts and 175 ethanol extracts) from 71 single plants, 97 mixtures of two plants, and seven formulations based on traditional medicine, to find herbal formulations to treat inflammatory bowel disease (IBD). In the in vitro screening, nitric oxide (NO), tumor necrosis factor (TNF)-α, and interleukin (IL)-6 levels were determined in LPS-treated RAW264...
January 28, 2019: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
Zhanjun Lu, Yangyang Hu, Sisi Li, Lijuan Zang, Weiliang Jiang, Jianjiong Wu, Xiening Wu, Yue Zeng, Xingpeng Wang
OBJECTIVE: To investigate the anti-inflammatory effect and mechanisms of interleukin-35 (IL-35) in inflammatory bowel disease. METHODS: BALB/c mice were divided into three groups with 10 mice in each group:control group, model group (oral administration of 4% glucan sodium sulfate for 7 d) and IL-35-treated group (oral administration of 4% glucan sodium sulfate for 7 d, intraperitoneal injection of 2 μg IL-35 at d2-5). Disease activity index (DAI) was scored every day...
May 25, 2018: Zhejiang da Xue Xue Bao. Yi Xue Ban, Journal of Zhejiang University. Medical Sciences
Abhinav Vasudevan, Peter R Gibson, Daniel R Van Langenberg
Background: Medication costs in inflammatory bowel disease (IBD) are now the principal driver of health care costs. Cost-effective strategies to optimize and rationalize treatment are therefore necessary. Methods: A systematic review until April 30, 2018, was performed to identify economic evaluations of strategies to optimize infliximab, adalimumab, and immunomodulators for the treatment of IBD in adults. A qualitative synthesis of the identified studies was performed...
January 25, 2019: Inflammatory Bowel Diseases
Konstantinos Papamichael, Anna Juncadella, Danny Wong, Shana Rakowsky, Lindsey A Sattler, James P Campbell, Byron P Vaughn, Adam S Cheifetz
Background & Aims: Therapeutic drug monitoring (TDM) has proven to be effective for optimizing anti-TNF therapy in inflammatory bowel disease (IBD). Nevertheless, the majority of data refer to infliximab and reactive testing or association studies. We aimed to compare the long-term outcome of patients with IBD who received at least one proactive TDM of adalimumab with standard of care, defined as empiric dose escalation and/or reactive TDM. Methods: This was a multicenter retrospective cohort study...
January 21, 2019: Journal of Crohn's & Colitis
Ming-Hsi Wang, Jessica J Friton, Laura E Raffals, Jonathan A Leighton, Shabana F Pasha, Michael F Picco, Kelly C Cushing, Kelly Monroe, Billy D Nix, Rodney D Newberry, William A Faubion
Background: It is important to identify patients with inflammatory bowel disease (IBD) refractory to anti-tumor necrosis factor (TNF) therapy to avoid potential adverse effects and adopt different treatment strategies. We aimed to identify and validate clinical and genetic factors to predict anti-TNF response in patients with IBD. Materials and Methods: Mayo Clinic and Washington University IBD genetic association study cohorts were used as discovery and replicate datasets, respectively...
January 21, 2019: Journal of Crohn's & Colitis
Bram Verstockt, Sare Verstockt, Jonas Dehairs, Vera Ballet, Helene Blevi, Willem-Jan Wollants, Christine Breynaert, Gert Van Assche, Séverine Vermeire, Marc Ferrante
BACKGROUND: With the changed therapeutic armamentarium for Crohn's disease (CD) and ulcerative colitis (UC), biomarkers predicting treatment response are urgently needed. We studied whole blood and mucosal expression of genes previously reported to predict outcome to anti-TNF therapy, and investigated if the signature was specific for anti-TNF agents. METHODS: We prospectively included 54 active IBD patients (24CD, 30UC) initiating anti-TNF therapy, as well as 22 CD patients initiating ustekinumab and 51 patients initiating vedolizumab (25CD, 26UC)...
January 23, 2019: EBioMedicine
Nina Roth, Luc Biedermann, Nicolas Fournier, Matthias Butter, Stephan R Vavricka, Alexander A Navarini, Gerhard Rogler, Michael Scharl
BACKGROUND/AIMS: Extraintestinal cutaneous manifestations of IBD represent a severe disease complication and an early and accurate treatment might positively influence the disease course. Using the patient collective of the Swiss IBD Cohort Study (SIBDCS), we analysed epidemiological as well as clinical factors being associated with the onset of pyoderma gangrenosum, erythema nodosum and aphthous ulcers in IBD patients. METHODS: We included 3266 SIBDCs patients, 1840 with Crohn's disease (CD) and 1426 with ulcerative colitis (UC) or IBD unclassified (IBDU) and analysed the association of cutaneous manifestations with age, age at diagnosis time, type of disease, gender, family history, HLA-allotype, smoking, intestinal disease activity, therapy and other extraintestinal manifestations (EIM)...
2019: PloS One
Jin Soo Moon
The incidence of pediatric inflammatory bowel disease (IBD) is increasing worldwide, especially in the developing countries. It differs from adult disease in clinical manifestations, especially with regard to genetic predisposition in monogenic IBD. Pediatric disease also have a tendency to show more aggressive inflammation and greater extent of lesion. Newer drugs such as anti-tumor necrosis factor α have been known to make a difference in treating pediatric IBD. Recent studies suggested that the patients with high risk factors might have some benefits from earlier use of biologics...
January 2019: Pediatric Gastroenterology, Hepatology & Nutrition
Yamile Zabana, Lorena Rodríguez, Triana Lobatón, Jordi Gordillo, Antonia Montserrat, Raquel Mena, Belén Beltrán, Marina Dotti, Olga Benitez, Jordi Guardiola, Eugeni Domènech, Esther Garcia-Planella, Xavier Calvet, Marta Piqueras, Montserrat Aceituno, Fernando Fernández-Bañares, Maria Esteve
INTRODUCTION: There is controversy as to whether the risk of relevant infection in IBD is related to immunosuppressants or the disease itself. AIMS: To evaluate: 1) the life-long prevalence and types of relevant infections in patients with IBD related to immunosuppressive treatment, and 2) the relationship of both infection and patient comorbidity to mortality. METHODS: Observational multicentre retrospective study of IBD patients that presented a relevant infection...
January 18, 2019: Journal of Crohn's & Colitis
Amarinder Singh, Pankaj Chibber, Praveen Kolimi, Tanveer Ahmad Malik, Nitika Kapoor, Amit Kumar, Narinder Kumar, Sumit G Gandhi, Surjeet Singh, Sheikh Tasduq Abdullah, Ram Vishwakarma, Gurdarshan Singh
Rohitukine (referred to as RHK) is a bioactive chromone alkaloid isolated from the leaves of plant Dysoxylum binectariferum, which has been reported to possess diverse pharmacological properties for the treatment of inflammatory bowel disease (IBD), diarrhoea and anti-lipidemic. However, the underlying mechanism by which RHK exerts its anti-inflammatory activity has not yet demonstrated. This study aimed to elucidate the anti-inflammatory mechanism of RHK using lipopolysaccharide (LPS) - stimulated J774A.1 macrophage cells and in-vivo inflammatory models...
January 18, 2019: International Immunopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"